USPTO Upholds Patentability of Genetic Technologies' IP | GenomeWeb

NEW YORK (GenomeWeb News) – Genetic Technologies announced today it received a further ex parte re-examination certificate from the US Patent and Trademark Office for certain claims related to the company's non-coding DNA patent.

The Australian firm said that the certificate follows the third request for ex parte re-examination by Duluth, Ga.-based Merial of claims 1-15, 17, 18, 26-29, and 32 of US Patent No. 5,612,179. In the certificate, the USPTO confirms the patentability of all the claims, and no amendments were made to the '179 patent, GTG said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.